Abbott Launches New Initiative to Drive Diversity in Medical Research and Improve Care Among Under-Represented Populations
ABBOTT PARK, Ill.,
People of diverse ethnic and cultural backgrounds make up nearly 40% of the
Funding and scholarships for future trial leaders
Through new partnerships with the four HBCU medical schools, the
Charles R. Drew University of Medicine and Science, the Howard University College of Medicine, Meharry Medical College, and the Morehouse School of Medicine, alongside the National Black Nurses Associationand National Association of Hispanic Nurses, Abbotthas dedicated $5 millionto fund nearly 300 scholarships over the next five years to support the next generation of ethnically diverse nurses, doctors and researchers who will lead and support future clinical trials. Increasing the diversity of doctors and nurses within the clinical trial landscape will also help advance trust in clinical research in diverse communities across the U.S.
Research Medical Advisory Board
Made up of leading independent doctors, trialists and health advocates,
Abbott'snew Diversity in Research Medical Advisory Board(MAB) will counsel on methods to reduce barriers to access within under-represented populations and communities of color and provide feedback on how Abbottcan continue to drive diversity enrollment within select company clinical trials.
Dedicated internal funding to improve access to
Abbottwill dedicate internal funding to improve access for women and under-represented communities within Abbotttrials. This funding will support additional trial sites for select Abbotttrials, new investigator training opportunities and trial components to eliminate barriers to participation such as transportation vouchers and interpreters where needed.
Convening Industry for Change
Abbottwill convene patient advocates, industry experts, trialists and a diverse set of physician thought leaders to develop and publish an open-source perspective to highlight key learnings around increasing clinical trial diversity across the health tech industry.
"The best health care product is a product that helps the most people, providing the greatest benefit. As an industry, we need to set new standards to make sure that our clinical trials remain representative of the people our products are designed to help," said
Clinical trials are the most effective way to understand how new medical devices, diagnostic tests, medicine, and therapies impact the health of human patients. They also represent opportunities to potentially treat patients battling complex conditions who haven't responded to traditional therapies.
Improving representation from diverse populations in clinical trials is paramount to reducing health disparities and better understanding the impact of the next generation of health care therapies across all populations. Yet according to the
In many communities, several barriers to access have historically disrupted enrollment into clinical trials, including lack of access to trial sites, a lack of clarity around the trial process, lack of trust and language barriers between patients and their physician. In addition, a shortage of diverse investigators leading trial sites – along with too few research nurses and research coordinators representing diverse communities – compound the challenge of increasing enrollment into clinical studies.
"The importance for people considering being a participant in a clinical trial to have a doctor or nurse who looks like them, who speaks their language and who understands their needs and those of their community cannot be overstated," said
Innovating for Greater Access and Equity in Health
To deliver results,
To learn more about
View original content:https://www.prnewswire.com/news-releases/abbott-launches-new-initiative-to-drive-diversity-in-medical-research-and-improve-care-among-under-represented-populations-301414718.html